Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

71.18EUR
11:39am EST
Change (% chg)

€0.35 (+0.49%)
Prev Close
€70.83
Open
€70.10
Day's High
€72.12
Day's Low
€70.09
Volume
4,183,157
Avg. Vol
2,187,374
52-wk High
€92.97
52-wk Low
€69.79

Chart for

About

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality... (more)

Overall

Beta: 0.92
Market Cap(Mil.): €89,467.79
Shares Outstanding(Mil.): 1,263.13
Dividend: 2.96
Yield (%): 4.18

Financials

  Industry Sector
P/E (TTM): -- 33.13 18.18
EPS (TTM): -- -- --
ROI: -- 14.97 33.32
ROE: -- 16.54 17.09

Celgene to buy Juno for $9 billion to boost cancer pipeline

Celgene Corp will pay $9 billion in cash to buy experimental cancer drugmaker Juno Therapeutics Inc, bulking up its developmental pipeline as it works to reduce reliance on its own cancer treatment Revlimid. | Video

Jan 22 2018

UPDATE 3-Celgene to buy Juno for $9 bln to boost cancer pipeline

* Juno's CAR-T drug could rake in $3 bln worldwide in peak sales (Adds background and analyst quote, updates share price)

Jan 22 2018

Biotech M&A takes off as Sanofi and Celgene spend $20 billion

Biotech deal activity exploded on Monday with French drugmaker Sanofi and U.S.-based Celgene spending a combined total of more than $20 billion to add new products for hemophilia and cancer to their medicine cabinets. | Video

Jan 22 2018

WRAPUP 2-Biotech M&A takes off as Sanofi and Celgene spend $20 billion

* Large drugmakers scour for products from smaller biotechs (Adds detail on gains in other biotech shares)

Jan 22 2018

Sanofi digs deep to buy U.S. hemophilia group Bioverativ for $11.6 billion

PARIS French healthcare group Sanofi has agreed to buy U.S. hemophilia specialist Bioverativ for $11.6 billion, its biggest deal for seven years and a major play to strengthen its presence in treatments for rare diseases. | Video

Jan 22 2018

UPDATE 5-Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 bln

* Shares in Sanofi down 4 percent (Updates shares, adds links to Breakingviews and other stories)

Jan 22 2018

BRIEF-Sanofi CFO sees commercial, cost and tax synergies following Bioverativ deal

Jan 22 Sanofi Chief financial officer Jerome Contamine says :

Jan 22 2018

BRIEF-Bioverativ Says Regarding Termination Of Merger Deal With Sanofi Under Certain Circumstances Co Will Be Required To Pay Fee Of $326 Mln

* BIOVERATIV SAYS REGARDING TERMINATION OF MERGER DEAL WITH SANOFI UNDER CERTAIN CIRCUMSTANCES CO WILL BE REQUIRED TO PAY FEE OF $326 MILLION - SEC FILING Source text: (http://bit.ly/2DC3sg7) Further company coverage:

Jan 22 2018

Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion

PARIS French healthcare group Sanofi has agreed to buy U.S. haemophilia specialist Bioverativ for $11.6 billion, its biggest deal for seven years, which it said would strengthen its presence in treatments for rare diseases. | Video

Jan 22 2018

US STOCKS-Futures slightly lower as U.S. shutdown enters third day

Jan 22 Wall Street was set to start the week slightly lower as a U.S. government shutdown entered its third day, while investors mulled over a flurry of multi-billion corporate mergers.

Jan 22 2018

Earnings vs. Estimates